Novel therapies in the treatment of irritable bowel syndrome

Expert Opinion on Investigational Drugs

Volumn 12, Issue 4, 2003, Pages 635-645

  Berrada, Driss ^a   Lembo, Tony ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

5 HT3 receptor antagonists; 5 HT4 receptor agonists; CCK receptor antagonists; Irritable bowel syndrome; Tachykinin receptor antagonists

Indexed keywords

ALOSETRON; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AYURVEDIC DRUG; CHINESE DRUG; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CILANSETRON; CLONIDINE; DEXLOXIGLUMIDE; DEXTROMETHORPHAN; DIGOXIN; GRANISETRON; LANEPITANT; LP 299V; MEBEVERINE; NEUROTROPHIN 3; ONDANSETRON; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROBIOTIC AGENT; PRUCALOPRIDE; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 ANTAGONIST; TACHYKININ RECEPTOR ANTAGONIST; TEGASEROD; THEOPHYLLINE; UNCLASSIFIED DRUG; WARFARIN;

ABDOMINAL DISCOMFORT; CARDIOTOXICITY; CLINICAL PRACTICE; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG TARGETING; FLATULENCE; FLUSHING; GALLSTONE FORMATION; GASTROENTEROLOGY; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; INJECTION SITE; INTESTINE MOTILITY; IRRITABLE COLON; ISCHEMIC COLITIS; LACTOBACILLUS PLANTARUM; NAUSEA; NONHUMAN; PARESTHESIA; PATHOPHYSIOLOGY; PERCEPTION; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; REVIEW; SENSATION; SKIN MANIFESTATION; SOMNOLENCE; SYMPTOM;

ANIMALS; CLINICAL TRIALS; COLONIC DISEASES, FUNCTIONAL; HUMANS; MEDICINE, HERBAL; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT3; RECEPTORS, SEROTONIN, 5-HT4; SEROTONIN AGONISTS;

EID: 0037396917     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.4.635     Document Type: Review

References (93)

1. SAITO YA, LOCKE GR, TALLEY NJ et al.: A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome. Am. J. Gastroenterol. (2000) 95(10):2816-2824.
2. LOCKE GR, YAWN BP, WOLLAN PC, LYDICK E: The incidence of clinically diagnosed irritable bowel syndrome in the community. Gastroenterology (1999) 116:A76.
3. CAMILLERI M, WILLIAMS DE: Economic burden of irritable bowel syndrome reappraised with strategies to control expenditures. Pharmacoeconomics (2000) 4: 331-338
4. LEVY RL, VON KORFF M, WHITEHEAD WE et al.: Costs of care for irritable bowel syndrome patients in a health maintenance organization. Am. J. Gastroenterol. (2001) 96(11):3122-3129.
5. GRALNEK IM, HAYS RD, KILBOURNE A, NALIBOFF B, MAYER EA: The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology (2000) 119(3):654-660.
6. BERTRAM S, KURLAND M, LYDICK E, LOCKE GR 3rd, YAWN BP: The patient's perspective of irritable bowel syndrome. J. Fam. Pract. (2001) 50(6):521-525.
7. EVERHART JE, RENAULT PF: Irritable bowel syndrome in office-based practice in the United States. Gastroenterology (1991) 100(4):998-1005.
8. YAWN BP, LOCKE GR 3rd, LYDICK E et al.: Diagnosis and care of irritable bowel syndrome in a community-based population. Am. J. Manag. Care (2001) 7(6):585-592.
9. DROSSMAN DA, CAMILLERI M, MAYER EA, WHITEHEAD WE: AGA technical review on irritable bowel syndrome. Gastroenterology (2002) 123(6):2108-2131.
10. THOMPSON WG, LONGSTRETH GF, DROSSMAN DA et al.: Functional bowel disorders and functional abdominal pain. Gut (1999) 45 (Suppl 2): II43-II47.
11. HORWITZ BJ, FISHER RS: The irritable bowel syndrome. N. Engl. J. Med. (2001) 344(24):1846-1850.
12. COLWELL LJ, PRATHER CM, PHILLIPS SF, ZINSMEISTER AR: Effects of an irritable bowel syndrome educational class on health-promoting behaviors and symptoms. Am. J. Gastroenterol (1998) 93(6):901-905.
13. WEEKS J: C. A. M. Complementary & alternative medicine. Mission & money in integrative medicine. Health forum J. (2001) 44(1):44.
14. YAN D, SCHULTE MK, BLOOM KE, WHITE MM: Structural features of the ligand-binding domain of the serotonin SHT3 receptor. J. Biol. Chem. (1999) 274(9):5537-5541.
15. FARTHING MJ: 5-Hydroxytryptamine and 5-hydroxytryptamine-3 receptor antagonists. Scand. J. Gastroenterol. Suppl. (1991) 188:92-100.
16. TALLEY NJ: Serotoninergic neuroenteric modulators. Lancet (2001) 358(9298):2061-2068.
17. HIGGINS GA, KILPATRICK GJ: 5-HT(3) receptor antagonists. Expert Opin. Investig. Drugs (1999) 8(12):2183-2188.
18. HUMPHREY PP, BOUNTRA C, CLAYTON N, KOZLOWSKI K: Review article: the therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome. Aliment. Pharmacol. Ther. (1999) 13(Suppl. 2):31-38.
19. TALLEY NJ: Review article: 5-hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: clinical implications. Aliment. Pharmacol. Ther. (1992) 6(3):273-289.
20. ZIGHELBOIM J, TALLEY NJ, PHILLIPS SF, HARMSEN WS, ZINSMEISTER AR: Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and serotonin Type 3 antagonism. Dig. Dis. Sci. (1995) 40(4):819-827.
21. 3 receptor antagonists in modulation of visceral hypersensitivity. Br. J. Pharmacol. (1995) 114(2):558-562.
22. 3-receptor antagonist, in patients with irritable bowel syndrome. Aliment. Pharmacol. Ther. (1993) 7(2):175-180.
23. STEADMAN CJ, TALLEY NJ, PHILLIPS SF, ZINSMEISTER AR: Selective 5-hydroxytryptamine Type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study. Mayo Clin. Proc. (1992) 67(8):732-738.
24. 3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment. Pharmacol. Ther. (2000) 14(6):775-782.
25. DELVAUX M, LOUVEL D, MAMET JP, CAMPOS-ORIOLA R, FREXINOS J: Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment. Pharmacol. Ther. (1998) 12(9):849-855.
26. 3 receptor antagonist Alosetron. Gastroenterology (2002) 123(4):969-977.
27. BARDHAN KD, BODEMAR G, GELDOF H et al.: A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment. Pharmacol. Ther. (2000) 14(1):23-34.
28. EDWARDS EB, HEITMAN CK, HALL P et al.: A twelve-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging, Phase II study to assess the clinical efficacy of alosetron (GR68755) in male subjects with irritable bowel syndrome. Am. J. Gatroenterol. (2001) 96(9):S317.
29. GUNPUT MD: Review article: clinical pharmacology of alosetron. Aliment. Pharmacol. Ther. (1999) 13(Suppl. 2):70-76.
30. 3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome. Am. J. Gastroenterol. (2001) 96(9):2671-2676.
31. KAMM MA: Review article: the complexity of drug development for irritable bowel syndrome. Aliment. Pharmacol. Ther. (2002) 16(3):343-351.
32. CAMILLERI M, NORTHCUTT AR, KONG S et al.: Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet (2000) 355(9209):1035-1040.
33. LEMBO T, WRIGHT RA, BAGBY B et al.: Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am. J. Gastroenterol. (2001) 96(9):2662-2670.
34. JONES RH, HOLTMANN G, RODRIGO L et al.: Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment. Pharmacol. Ther. (1999) 13(11):1419-1427.
35. WATSON ME, LACEY L, KONG S et al.: Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome. Am. J. Gastroenterol. (2001) 96(2):455-459.
36. JHINGRAN P, DECKER C, WATSON M, NORTHCUTT A, RICCI JF: Alosetron reduces time lost from work in women with diarrhoea-predominant irritable bowel syndrome. Clin. Drug Invest. (2001) 21(12):843-852.
37. 3 receptor antagonist. Aliment. Pharmacol. Ther. (1999) 13(9):1149-1159.
38. FRIEDEL D, THOMAS R, FISHER RS: Ischemic colitis during treatment with alosetron. Gastroenterology (2001) 120(2):557-560.
39. Alosetron (lotronex). Med. Lett. (5 August 2002)44.
40. STACHER G: Cilansetron. Solvay. Curr. Opin. Investig. Drugs (2001) 2(10):1432-1436.
41. CAMILLERI M: Review article: tegaserod. Aliment. Pharmacol. Ther. (2001) 15(3):277-289.
42. CALLAHAN MJ: Irritable bowel syndrome neuropharmacology. A review of approved and investigational compounds. J. Clin. Gastroenterol. (2002) 35(1, Suppl.):S58-S67.
43. PFANNKUCHE HJ, BUHL T, GAMSE R et al.: The properties of a new prokinetically active drug SDZ HTF 919. Neurogastroenterol. Motil. (1995) 7:280.
44. PRATHER CM, CAMILLERI M, ZINSMEISTER AR, MCKINZIE S, THOMFORDE G: Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology (2000) 118(3):463-468.
45. SCHIKOWSKI A, THEWISSEN M, MATHIS C, ROSS HG, ENCK P: Serotonin type-4 receptors modulate the sensitivity of intramural mechanoreceptive afferents of the cat rectum. Neurogastroenterol. Motil. (2002) 14(3):221-227.
46. 4 receptor partial agonist colorectal distension in rats. Gastroenterology (2000) 118(4):A835:4393.
47. 4 receptor agonist. Gastroenterology (1999) 116(4):A643:G2805.
48. NOVARTIS: Zelmac (tegaserod). Advisory Committee briefing document, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA (2000).
49. BAKER DE: Tegaserod for the treatment of constipation-predominant irritable bowel syndrome. Rev. Gastroenterol Disord. (2001). 1(4):187-198.
50. LANGAKER KJ, MORRIS D, PRUITT R et al.: The partial 5-HT4 agonist (HTF 919) improves symptoms in constipation-predominant irritable bowel syndrome (C-IBS). Digestion (1998) 59(Suppl. 3):20.
51. MULLER-LISSNER SA, FUMAGALLI I, BARDHAN KD et al.: Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment. Pharmacol. Ther. (2001) 15(10):1655-1666.
52. NOVICK J, MINER P, KRAUSE R et al.: A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment. Pharmacol. Ther. (2002) 16(11):1877-1888.
53. LEFKOWITZ MP, RUEGG P, SHI Y et al.: Relief of overall GI symptoms and abdominal pain and discomfort as outcome measures in a clinical trial of irritable bowel syndrome with HTF 919. Gastroenterology (1999) 116:A1027.
54. BOURAS EP, CAMILLERI M, BURTON DD, MCKINZIE S: Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut (1999) 44(5):682-686.
55. EMMANUEL AV, KAMM MA, ROY AJ, ANTONELLI K: Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers. Gut (1998) 42(4):511-516.
56. BOURAS EP, CAMILLERI M, BURTON DD et al.: Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology (2001) 120(2):354-360.
57. EMMANUEL AV, ROY AJ, NICHOLLS TJ, KAMM MA: Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment. Pharmacol. Ther. (2002) 16(7):1347-1356.
58. OTTEN MH, SCHNEIDER H, WURZER H et al.: doubleblind, placebo controlled evaluation of safety and efficacy of 12 week, twice daily treatment with prucalopride in patients with chronic constipation. Gastroenterology (1999) 116(4):A1055.
59. JOHANSON JR, MINER PB, PARKMAN HP et al.: Prucalopride improves bowel movement frequency and symptoms in patients with chronic constipation: results of two double-blind, placebo-controlled trials. Gastroenterology (2000) 118(4):A175.
60. BONNAFOUS C, BUENO L, GRIFFIN PH et al.: Influence of dexloxiglumide on visceromotor and pain response induced by rectal distension in rats. Gastroenterology (2002) 122:A527.
61. VARGA G: Dexloxiglumide Rotta Research Lab. Curr. Opin. Investig. Drugs (2002) 3:621-626.
62. MEIER R, GLACOVELLI G, D'AMATO M: Effect of the CCK-A receptor antagonist dexloxiglumide on post-prandial gallbladder emptying and colonic transit time in healthy volunteers. Gut (1997)41.
63. D'AMATO M, WHORWELL PJ, THOMPSON DG et al.: The CCK1 receptor antagonist dexloxiglumide does not increase the risk of gallstone formation. Am. J. Gastroenterol. (2001) 96(9):S316-S317.
64. LECCI A, VALENTI C, MAGGI CA: Tachykinin receptor antagonists in irritable bowel syndrome. Curr. Opin. Investig. Drugs (2002) 3(4):589-601.
65. JULIA V, MORTEAU O, BUENO L: Involvement of neurokinin 1 and 2 receptors in viscerosensitive response to rectal distension in rats. Gastroenterology (1994) 107(1):94-102.
66. LORDAL M, NAVALESI G, THEODORSSON E, MAGGI CA, HELLSTROM PM: A novel tachykinin NK2 receptor antagonist prevents motility-stimulating effects of neurokinin A in small intestine. Br. J. Pharmacol. (2001) 134(1):215-223.
67. GOLDSTEIN DJ, WANG O, GITTER BD, IYENGAR S: Dose-response study of the analgesic effect of lanepitant in patients with painful diabetic neuropathy. Clin. Neuropharmacol. (2001) 24(1):16-22.
68. GOLDSTEIN DJ, WANG O, TODD LE et al.: Study of the analgesic effect of lanepitant in patients with osteoarthritis pain. Clin. Pharmacol. Ther. (2000) 67(4):419-426.
69. GOLDSTEIN DJ, OFFEN WW, KLEIN EG et al.: Lanepitant, an NK-1 antagonist, in migraine prevention. Cephalalgia (2001) 21(2):102-106.
70. A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III). Neurology (1999) 52(7):1427-1433.
71. COULIE B, SZARKA LA, CAMILLERI M et al.: Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans. Gastroenterology (2000) 119(1):41-50.
72. PARKMAN HP, MINER PB, RAO SSC et al.: NT-3 improves functional constipation. Am. J. Gastroenterol. (2001) 96(9):S160-S161.
73. LOHOF AM, IP NY, POO MM: Potentiation of developing neuromuscular synapses by the neurotrophins NT-3 and BDNF. Nature (1993) 363(6427):350-353.
74. COULIE B, LEE JS, LYFORD G, CAMILLERI M: Recombinant human neurotrophin-3 increases noncholinergic smooth muscle contractility and decreases nonadrenergic noncholinergic (NANC) inhibition of myenteric neurons in guinea-pig colon. Gastroenterology (2000) 118:A710.
75. GILLIS RA, DIAS SOUZA J, HICKS KA et al.: Inhibitory control of proximal colonic motility by the sympathetic nervous system. Am. J. Physiol. (1987) 253(4, Pt 1):G531-G539.
76. NESS TJ, GEBHART GF: Differential effects of morphine and clonidine on visceral and cutaneous spinal nociceptive transmission in the rat. J. Neurophysiol. (1989) 62(1):220-230.
77. BONNET F, BOICO O, ROSTAING S et al.: Postoperative analgesia with extradural clonidine. Br. J. Anaesth. (1989) 63(4):465-469.
78. TREMLETT MR, KELLY PJ, PARKINS J, HUGHES D, REDFERN N: Low-dose clonidine infusion during labour. Br. J. Anaesth. (1999) 83(2):257-261.
79. BUERKLE H, HUGE V, WOLFGART M et al.: Intra-articular clonidine analgesia after knee arthroscopy. Eur. J. Anaesthesiol. (2000) 17(5):295-299.
80. RUBINOFF MJ, PICCIONE PR, HOLT PR: Clonidine prolongs human small intestine transit time: use of the lactulose-breath hydrogen test. Am. J. Gastroenterol. (1989) 84(4):372-374.
81. MORALI GA, BRAVERMAN DZ, LISSI J, GOLDSTEIN R, JACOBSOHN WZ: Effect of clonidine on gallbladder contraction and small bowel transit time in insulin-treated diabetics. Am. J. Gastroenterol. (1991) 86(8):995-999.
82. BHARUCHA AE, CAMILLERI M, ZINSMEISTER AR, HANSON RB: Adrenergic modulation of human colonic motor and sensory function. Am. J. Physiol. (1997) 273(5, Pt 1):G997-G1006.
83. MALCOLM A, CAMILLERI M, KOST L et al.: Towards identifying optimal doses for alpha-2 adrenergic modulation of colonic and rectal motor and sensory function. Aliment. Pharmacol. Ther. (2000) 14(6):783-793.
84. PRIOR A, WILSON KM, WHORWELL PJ: Double-blind study of an alpha 2 agonist in the treatment of irritable bowel syndrome. Aliment. Pharmacol. Ther. (1988) 2(6):535-539.
85. VIRAMONTES BE, MALCOLM A, CAMILLERI M et al.: Effects of an alpha(2)-adrenergic agonist on gastrointestinal transit, colonic motility, and sensation in humans. Am. J. Physiol. Gastrointest. Liver Physiol. (2001) 281(6):G1468-G1476.
86. DUNNE C: Adaptation of bacteria to the intestinal niche: probiotics and gut disorder. Inflamm. Bowel Dis. (2001) 7(2):136-145.
87. HUNTER JO, MADDEN JA: A review of the role of the gut microflora in irritable bowel syndrome and the effects of probiotics. Br. J. Nutr. (2002) 88(Suppl. 1):67-72.
88. O'SULLIVAN GC: Probiotics. Br. J. Surg. (2001) 88(2):161-162.
89. BRIGIDI P, VITALI B, SWENNEN E, BAZZOCCHI G, MATTEUZZI D: Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. Res. Microbiol. (2001) 152(8):735-741.
90. NIEDZIELIN K, KORDECKI H, BIRKENFELD B: A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur. J. Gastroenterol. Hepatol. (2001) 13(10):1143-1147.
91. O'SULLIVAN MA, O'MORAIN CA: Bacterial supplmentation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Dig. Liver Dis. (2000) 32(4):294-301.
92. BENSOUSSAN A, TALLEY NJ, HING M et al.: Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. JAMA (1998) 280(18):1585-1589.
93. AGNIHOTRI MS: Ayurved (ancient Indian system of medicine) and modern molecular medicine. J. Assoc. Physicians India (2000) 48(3):366-367.